Investigating how to improve the clearance of harmful proteins in Alzheimer's disease
Mechanisms and therapeutic potential of the autophagy-lysosome pathway in Alzheimer’s disease
This study is looking at how a protein called TFEB helps clear out harmful substances in the brain related to Alzheimer's disease, and it hopes to find new ways to improve treatments for patients by figuring out how to boost this protein's activity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11062938 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms that regulate a key protein, TFEB, which plays a crucial role in the autophagy-lysosomal pathway involved in Alzheimer's disease. By studying how certain proteins influence TFEB and the clearance of tau aggregates, the research aims to identify potential therapeutic targets that could help mitigate the progression of Alzheimer's. The approach includes both genetic and pharmacological methods to explore how inhibiting specific proteins can enhance the body's ability to clear harmful substances associated with Alzheimer's. Patients may benefit from new treatment strategies that arise from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease or are at risk for developing it.
Not a fit: Patients under the age of 65 or those without Alzheimer's disease may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve the clearance of toxic proteins in Alzheimer's disease, potentially slowing its progression.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for Alzheimer's treatment, indicating that this approach could be a viable avenue for further exploration.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Li, Yueming — Sloan-Kettering Inst Can Research
- Study coordinator: Li, Yueming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.